MCM
VIVO

Matarin Capital Management’s Meridian Bioscience Inc VIVO Stock Holding History

Matarin Capital Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-65,115
Closed -$774K – 275
2019
Q2 		$774K Sell
65,115
-134,187
-67% -$1.62M 0.06% 222
2019
Q1 		$3.51M Buy
199,302
+11,140
+6% +$185K 0.26% 139
2018
Q4 		$3.27M Buy
188,162
+93,648
+99% +$1.6M 0.26% 139
2018
Q3 		$1.41M Buy
+94,514
New +$1.47M 0.09% 193

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Matarin Capital Management's VIVO Position: Q3 2019 in Review

Matarin Capital Management sold out of Meridian Bioscience Inc (VIVO) in Q3 2019, closing a stake of 65,115 shares — an estimated $774K sold.

Matarin Capital Management first reported a position in VIVO in Q3 2018 and held it in 4 quarters. The position peaked at $3.51M in Q1 2019. 163 funds tracked by Wall St. Rank hold VIVO as of Q3 2019.

  • Matarin Capital Management reported no remaining Meridian Bioscience Inc position as of Q3 2019 after selling out during the quarter.
  • Matarin Capital Management sold 65,115 Meridian Bioscience Inc shares in Q3 2019, an estimated $774K.
  • Matarin Capital Management first reported a position in Meridian Bioscience Inc in Q3 2018 and held it in 4 quarters.
  • Matarin Capital Management's Meridian Bioscience Inc position peaked at $3.51M in Q1 2019.
  • 163 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2019.

Based on Matarin Capital Management's 13F filing for Q3 2019, filed 5 Nov 2019.